Hua Medicine (Shanghai) Ltd.

2552

KYG4644K1022

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
1.62 ^HKD	+1.89%		+8.00%	-17.77%

Mar. 28	Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024	CI

Hua Medicine Ltd.(SEHK:2552) added to S&P Global BMI Index

September 21, 2020 at 12:00 am EDT

Hua Medicine (Shanghai) Ltd.(SEHK:2552) added to S&P Global BMI Index

Latest news about Hua Medicine (Shanghai) Ltd.

Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024	Dec. 29	CI
Hua Medicine Intends to Conduct Trials of Diabetes Drug in US	Dec. 21	MT
Hua Medicine Submits Investigational New Drug Application with the U.S. Food and Drug Administration for the 2Nd Generation Glucokinase Allosteric Activator	Dec. 20	CI
China Includes Hua Medicine's Type 2 Diabetes Medication in Drug Reimbursement List	Dec. 14	MT
Hua Medicine's Unit Receives 800 Million Yuan for Development of Diabetes Drug	Nov. 22	MT
Hua Medicine Ltd. Announces Board and Committee Changes	23-10-12	CI
Transcript : Hua Medicine Ltd., Q2 2023 Earnings Call, Aug 25, 2023	23-08-24
Hua Medicine Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Hua Medicine Signs Distribution Agreement with Digital Healthcare Platform	23-04-11	MT
Hua Medicine Ltd. Announces Resignation of Mr. Junling Liu as Independent Non-Executive Director and Change in Composition of the Board Committees	23-03-30	CI
Transcript : Hua Medicine Ltd., 2022 Earnings Call, Mar 30, 2023	23-03-29
Hua Medicine Shrinks Loss in 2022 as Revenue Witnesses a Boost	23-03-29	MT
Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Hua Medicine Makes 49 Million Yuan of HuaTangNing Sales Since Launch	23-02-17	MT
Hua Medicine Receives 400 Million Yuan in Milestone Payments for Diabetes Treatment	23-02-07	MT
Hua Medicine Ltd. Announces Directorate and Committee Changes	22-12-29	CI
Hua Medicine Announces Demise of Walter Teh-Ming Kwauk, an Independent Non-Executive Director	22-11-24	CI
Hua Medicine Unit Buys 100% Stake in Diabetes Drug Research Company	22-11-18	MT
China OKs Hua Medicine's New Drug Application for Type 2 Diabetes Treatment; Shares slipped 11%	22-10-09	MT
Hua Medicine Announces Approval of NDA of Huatangning, Innovative First-In-Class GKA Potential Inside Information	22-10-09	CI
Hua Medicine Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Hua Medicine Narrows Loss in 2021 as Expenses Fall	22-03-17	MT
Transcript : Hua Medicine Ltd., 2021 Earnings Call, Mar 17, 2022	22-03-16
Hua Medicine Ltd. Announces Board Changes	22-03-16	CI

Chart Hua Medicine (Shanghai) Ltd.

Duration

Period

More charts

Hua Medicine is a China-based company principally engaged in the drug development business. The Company is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The Company mainly operates its business in the domestic and overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-06-26 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Hua Medicine (Shanghai) Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.5 CNY

Average target price

3.072 CNY

Spread / Average Target

+104.89%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
HUA MEDICINE (SHANGHAI) LTD.	-17.77%	199M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.71B
ARGENX SE	+1.69%	22.02B
BIONTECH SE	-17.37%	20.9B
GENMAB A/S	-9.30%	17.85B
WUXI APPTEC CO., LTD.	-41.01%	16.21B
BEIGENE, LTD.	-14.85%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.86B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.04B

Bio Therapeutic Drugs

Hua Medicine (Shanghai) Ltd.

Equities

2552

KYG4644K1022

Biotechnology & Medical Research

Hua Medicine Ltd.(SEHK:2552) added to S&P Global BMI Index

Latest news about Hua Medicine (Shanghai) Ltd.

Chart Hua Medicine (Shanghai) Ltd.

Company Profile

Income Statement Evolution

Ratings for Hua Medicine (Shanghai) Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs